Business context and reporting period
Important identity mismatch: The supplied filing is Priveterra Acquisition Corp.’s Form 10-Q, not an AEON Biopharma filing. It covers the quarter ended September 30, 2021. Priveterra was a blank-check company seeking a business combination and reported no operating activity or revenue before such a transaction.
Financial results and position
- Revenue and margins: No operating revenue; margins are not meaningful for this pre-combination SPAC.
- Net income: $5.66 million for Q3 and $7.95 million for the nine months ended September 30, 2021. Results were driven chiefly by noncash unrealized gains on warrants of $6.09 million and $9.60 million, respectively. Formation and operating costs were $450,892 for Q3 and $1.05 million year to date.
- Cash flow: Nine-month operating cash use was $1.33 million; investing cash use was $276.00 million, reflecting trust funding; financing provided $278.00 million. Ending cash outside the trust was $663,540.
- Assets and liquidity: Total assets were $277.20 million, including $276.06 million in the trust account. Reported working capital was approximately $954,716 excluding franchise tax payable. Management said available working capital and borrowing capacity should cover needs until a business combination or one year from filing.
- Liabilities and equity: Total liabilities were $22.20 million, including an $8.50 million warrant liability and $9.66 million deferred underwriting discount payable only if a business combination closes. Stockholders’ deficit was $17.18 million. Public shares subject to possible redemption were recorded as $276.00 million of temporary equity.
- Debt: No working capital loan borrowings were outstanding at quarter-end; $100,000 of loans had been converted into warrants in June. A $3,495 related-party payable remained.
Changes and unusual items
The company revised its prior-period presentation to classify all public shares as temporary equity, rather than partly as permanent equity, and revised earnings-per-share allocations between Class A and Class B shares. Management said the effects were not material to previously presented financial statements. The warrant fair-value gain substantially influenced reported income and is not operating performance or cash generation. No comparative 2020 operating period is presented in the statements provided.
Outlook, risks and contingencies
- Priveterra had 24 months from its February 11, 2021 IPO—through February 11, 2023—to complete a business combination, or it would liquidate and redeem public shares, subject to the filing’s terms.
- Management warned that COVID-19 could adversely affect the search for a target or financial position, but the impact was not determinable.
- The $9.66 million deferred underwriting fee is contingent on completing a business combination. Trust assets may also be exposed to certain creditor claims; sponsor indemnification is not assured because the company had not verified the sponsor’s ability to pay.
- The filing reports no legal proceedings, no off-balance-sheet arrangements, and no material change in previously disclosed risk factors. Management concluded disclosure controls were effective.
Investor facts to verify
- Confirm the filing entity: this document is for Priveterra Acquisition Corp., not AEON Biopharma, Inc.
- Review the warrant valuation and its large noncash contribution to earnings, including the Level 3 assumptions for private warrants.
- Check the business-combination deadline and redemption terms; the filing contains differing references to an 18-month period versus a 24-month period.
- Assess the trust balance, redemption classification, deferred underwriting fee, and sponsor’s capacity to meet any indemnification obligations.